[Tianfeng Medical Yang Song Team] Huahai Pharmaceutical Update: First Innovative Drug Approved, Innovation Transition Enters Harvest Period

English summary

### [Tianfeng Medical Yang Song Team] Huahai Pharmaceutical Update: First Innovative Drug Approved, Innovation Transition Enters Harvest Period Time: 2026-07-30 08:09:59 Content: [Tianfeng Medical Yang Song Team] Huahai Pharmaceutical Update: First Innovative Drug Approved, Innovation Transition Enters Harvest Period $Huahai Pharmaceutical(SH600521)$ Event: On July 29, 2026, the company's first innovative drug, IL-36 monoclonal antibody, was approved for marketing in China, indicated for generalized pustular psoriasis. It is the second globally and the first IL-36 monoclonal antibody approved in China. # Efficacy: Registered Phase II clinical data showed that after one week of dosing, the pustule clearance rate of the company's IL-36 reached 77.8%, outperforming the competitor's 59% (non-head-to-head), with significant efficacy. We are optimistic about the domestic commercialization potential of the company's first innovative drug in the niche track and its overseas licensing potential.…